Vanguard Capital Management’s Immuneering IMRX Stock Holding History
Bought
Maintained
Sold
Other funds holding IMRX
DA
Vanguard Capital Management's IMRX Position: Q3 2026 in Review
Vanguard Capital Management reduced its Immuneering (IMRX) stake by 0.07% in Q3 2026, selling an estimated $7.33K and leaving 2,284,882 shares worth $9.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2799.
Vanguard Capital Management first reported a position in IMRX in Q1 2026 and has held it in 3 quarters since. The position peaked at $12.1M in Q1 2026. 131 funds tracked by Wall St. Rank hold IMRX as of Q3 2026.
- Vanguard Capital Management held 2,284,882 shares of Immuneering worth $9.36M as of Q3 2026.
- Vanguard Capital Management sold 1,552 Immuneering shares in Q3 2026, an estimated $7.33K.
- Immuneering made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2799 holding.
- Vanguard Capital Management first reported a position in Immuneering in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Immuneering position peaked at $12.1M in Q1 2026.
- 131 funds tracked by Wall St. Rank held Immuneering as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.